CBD and Sleep: What the Evidence Really Says About Stress, Anxiety, and Insomnia

Author: Rohan Smith | Functional Medicine Practitioner | Adelaide, SA

Quick Answer

CBD (cannabidiol) may influence stress and sleep by interacting indirectly with the endocannabinoid system (ECS), serotonin signalling, and the hypothalamic–pituitary–adrenal (HPA) axis. Current evidence suggests CBD may be associated with reduced anxiety and improved sleep in some individuals—particularly where hyperarousal, pain, or chronic stress are contributing factors. Clinical responses remain variable, evidence quality is mixed, and CBD should be viewed as a complementary support rather than a primary treatment for stress-related sleep disturbance.

Understanding CBD: What It Is—and What It Is Not

Cannabidiol (CBD) is a non-intoxicating phytocannabinoid derived from Cannabis sativa. Unlike tetrahydrocannabinol (THC), CBD does not produce psychoactive effects. Most commercially available CBD products are extracted from hemp varieties containing minimal THC.

Importantly, CBD is not a sedative, hypnotic, or conventional anxiolytic medication. Its effects appear to be regulatory rather than suppressive, influencing multiple neurobiological systems involved in stress adaptation and sleep–wake balance.

The Endocannabinoid System and Stress Physiology

The endocannabinoid system (ECS) is a regulatory network involved in maintaining physiological balance (homeostasis). It plays a recognised role in stress responsiveness, emotional regulation, immune signalling, pain perception, and sleep–wake cycling.

CBD does not directly activate cannabinoid receptors (CB1 or CB2). Instead, it appears to influence overall ECS tone by modulating endocannabinoid degradation, receptor sensitivity, and cross-talk with other neurotransmitter systems, including serotonin (5-HT1A) and gamma-aminobutyric acid (GABA).

CBD, Cortisol, and the Stress Response

Chronic psychological stress is associated with dysregulation of the HPA axis and altered cortisol rhythms. In Adelaide-based clinical practice, stress-related sleep disturbance is more commonly driven by nervous system hyperarousal than by a primary sleep disorder.

Some experimental and clinical studies suggest CBD may attenuate stress-induced cortisol responses and reduce physiological reactivity in anxiety-provoking situations. These effects are not consistent across individuals and appear to depend on dose, timing, and baseline neurobiology. CBD does not function as a direct hormonal therapy.

CBD and Anxiety-Related Sleep Disturbance

Anxiety is a common contributor to sleep-onset insomnia and nocturnal awakenings. Several human studies have reported reductions in subjective anxiety following acute or short-term CBD administration, which may indirectly support sleep initiation in certain individuals.

CBD’s potential anxiolytic effects appear to involve serotonergic signalling and limbic system modulation rather than sedation. This profile may be most relevant for individuals experiencing stress-related anxiety and nervous system dysregulation, as explored further in our mental health physiology resources.

CBD and Sleep Quality: What the Evidence Shows

Research examining CBD and sleep remains limited and heterogeneous. Some studies report improvements in sleep duration or perceived sleep quality, while others demonstrate neutral effects. Outcomes appear to vary depending on whether sleep disturbance is driven by anxiety, pain, inflammation, or neurological hyperarousal.

Notably, CBD does not consistently improve sleep architecture and should not be considered a substitute for investigating underlying drivers of insomnia or non-restorative sleep.

Safety, Interactions, and Clinical Caution

CBD is generally well tolerated, but it is not without risk. Reported adverse effects include gastrointestinal discomfort, fatigue, appetite changes, and dizziness. More importantly, CBD can inhibit cytochrome P450 enzymes, potentially altering the metabolism of medications such as antidepressants, benzodiazepines, antiepileptics, and anticoagulants.

For this reason, CBD should not be used without professional guidance in individuals taking prescription medications or managing complex chronic health conditions.

Practical Considerations (Not Prescriptive Advice)

• Product quality varies significantly between manufacturers
• Third-party laboratory testing is essential
• Clinical responses are dose-dependent and often non-linear
• Individual sensitivity differs widely
• CBD should be considered an adjunct, not a primary intervention

When CBD May Be Considered

CBD may be explored as part of a broader functional medicine strategy when anxiety, pain, or nervous system hyperarousal contribute to poor sleep—particularly after foundational factors such as sleep hygiene, circadian alignment, and nutrient status have been addressed.

Next Steps: A Functional Medicine Perspective

At Elemental Health and Nutrition, sleep disturbance is approached as a systems-level issue. Persistent insomnia or non-restorative sleep often reflects deeper physiological dysregulation, including altered stress signalling, inflammatory burden, or metabolic strain.

Rather than focusing on a single supplement, clinical assessment may include evaluation of stress physiology, circadian rhythm disruption, and drivers commonly associated with chronic fatigue and persistent exhaustion. CBD, where appropriate, is considered within this broader clinical context—not as a standalone solution.

Key Insights

• CBD may influence stress and sleep indirectly through regulatory neurobiological pathways
• Potential benefits appear most relevant for anxiety-related sleep disturbance
• Clinical responses vary significantly between individuals
• CBD does not replace appropriate investigation of sleep or fatigue disorders

Looking for Clinical Guidance in Adelaide?

If you are experiencing persistent stress-related sleep issues or fatigue, a personalised assessment may help clarify the underlying drivers. Functional medicine care focuses on understanding why sleep disruption is occurring, rather than masking symptoms.

References

1. Russo EB. Cannabidiol claims and misconceptions. Trends in Pharmacological Sciences. 2017.
2. Hill MN, Campolongo P, Yehuda R, Patel S. Integrating endocannabinoid signaling and cannabinoids into the biology of stress. Nature Reviews Neuroscience. 2018.
3. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the therapeutic potential of cannabidiol in psychiatric disorders. Current Neuropharmacology. 2016.
4. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: A large case series. The Permanente Journal. 2019.
5. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of anxiety disorders. Journal of Psychopharmacology. 2017.
6. Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: A review of the literature. Current Psychiatry Reports. 2017.
7. Molero Y, Zetterqvist J, Binswanger IA, Hellner C, Larsson H, Fazel S. Medications for insomnia and risk of mortality. Sleep Medicine Reviews. 2020.
8. Hillard CJ. Stress regulates endocannabinoid–CB1 receptor signaling. Neuropsychopharmacology. 2014.
9. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015.
10. Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Sleep Medicine. 2022.
11. Brown JD, Winterstein AG. Potential adverse drug events and drug–drug interactions with cannabidiol. Epilepsy & Behavior. 2019.
12. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol. Cannabis and Cannabinoid Research. 2017.
13. VanDolah HJ, Bauer BA, Mauck KF. Clinicians’ guide to cannabidiol and hemp oils. Journal of the American Pharmacists Association. 2019.
14. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015.
15. Hoch E, Bonnetn U, Thomasius R, et al. Risks associated with the non-medicinal use of cannabis. Dialogues in Clinical Neuroscience. 2019.